Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
85.64
+2.29 (2.75%)
Nov 20, 2024, 4:00 PM EST - Market closed
Intra-Cellular Therapies Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for ITCI stock have an average target of 97.67, with a low estimate of 74 and a high estimate of 130. The average target predicts an increase of 14.05% from the current stock price of 85.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ITCI stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 5 | 5 | 4 | 4 | 5 | 5 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $81 → $89 | Buy | Maintains | $81 → $89 | +3.92% | Nov 4, 2024 |
| Needham | Needham | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +16.77% | Oct 31, 2024 |
| Needham | Needham | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +16.77% | Oct 30, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $92 → $95 | Buy | Maintains | $92 → $95 | +10.93% | Oct 11, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $106 → $108 | Buy | Maintains | $106 → $108 | +26.11% | Oct 4, 2024 |
Financial Forecast
Revenue This Year
688.41M
from 464.37M
Increased by 48.25%
Revenue Next Year
953.21M
from 688.41M
Increased by 38.47%
EPS This Year
-0.70
from -1.46
EPS Next Year
0.27
from -0.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 715.1M | 1.1B | 1.7B | ||
| Avg | 688.4M | 953.2M | 1.4B | ||
| Low | 652.2M | 839.9M | 1.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 54.0% | 57.9% | 79.5% | ||
| Avg | 48.2% | 38.5% | 48.4% | ||
| Low | 40.4% | 22.0% | 15.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.37 | 1.39 | 6.33 | ||
| Avg | -0.70 | 0.27 | 3.61 | ||
| Low | -1.04 | -0.92 | 1.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 2,267.9% | ||
| Avg | - | - | 1,250.0% | ||
| Low | - | - | 446.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.